• Profile

Drug-drug interaction potential in men treated with enzalutamide: Mind the gap

British Journal of Clinical Pharmacology Sep 12, 2017

Benoist GE, et al. – In this assessment, the clinicians evaluated the prevalence of potential drug-drug interactions (DDIs) in metastatic castration resistant prostate cancer (mCRPC) patients treated with enzalutamide. They reported a high prevalence of potential DDIs. Between the three drug interaction compendia, the inclusion and grading of potential DDIs were highly variable. This problem requires a critical concern from physicians, nurses, and pharmacists, in order to implement intensive monitoring or alternative treatment strategies to prevent suboptimal treatment of the co-morbidities in patients treated with enzalutamide.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
  • 55 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Unlimited access to original articles by experts
  • Nonloggedinlock icon
    Secure: we never sell your data
  • Signing up takes less than 2 mins
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen